EXPERT SUMMARIES of the top 30 journals in hematology & oncology
 Personalize your search
In the Journals Plus

Gastroenteropancreatic neuroendocrine tumor recurrence often occurs late

Singh S, et al. JAMA Oncol. 2018;doi:10.1001/jamaoncol.2018.0024.
Disease recurrence occurs significantly later for patients with gastroenteropancreatic neuroendocrine tumors compared with other gastrointestinal…
In the Journals Plus

World Trade Center responders may face increased cancer burden, elevated myeloma risk

Brawley OW. JAMA Oncol. 2018;doi:10.1001/jamaoncol.2018.0498.
Landgren O, et al. JAMA Oncol. 2018;doi:10.1001/jamaoncol.2018.0509.
Singh A, et al. JAMA Oncol. 2018;doi:10.1001/jamaoncol.2018.0504.
Rescue and recovery workers who responded to the World Trade Center site after 9/11 will experience a greater cancer burden over the next 20 years…
In the Journals Plus

Analysis determines true cost for CAR T-cell therapy

Hernandez I, et al. JAMA Oncol. 2018;doi:10.1001/jamaoncol.2018.0977.
Patients treated with chimeric antigen receptor T-cell therapy will incur on average $30,000 to $36,000 in additional costs aside from drug expenses…
In the Journals Plus

Dasatinib active in certain patients with imatinib-resistant gastrointestinal stromal tumors

Schuetze SM, et al. JAMA Oncol. 2018;doi:10.1001/jamaoncol.2018.0601.
Dasatinib demonstrated antitumor activity among a subset of patients with imatinib-resistant gastrointestinal stromal tumors, according to results of…
In the Journals Plus

Type 2 diabetes linked to renal cell carcinoma risk in women

Graff RE, et al. Diabetes Care. 2018;doi:10.2337/dc17-2518.
Type 2 diabetes is associated with an increased risk for renal cell carcinoma in women, independent of other risk factors, such as obesity and…
In the Journals Plus

Study reveals association between industry payments and physicians’ treatment choices

Mitchell AP, et al. JAMA Intern Med. 2018;doi:10.1001/jamainternmed.2018.0776.
Oncologists who received general payments from a pharmaceutical company appeared more likely to prescribe a drug marketed by that company, according…
In the Journals Plus

Eltrombopag provides long-term disease control in immune thrombocytopenia

Wong RSM, et al. Blood. 2017;doi:10.1182/blood-2017-04-748707.
Adults with chronic or persistent immune thrombocytopenia maintained ideal platelet counts and decreased bleeding rate after treatment with…
In the Journals Plus

‘Soft’ chemotherapy delays breast cancer progression for elderly

Wildiers H, et al. Lancet Oncol. 2018;doi:10.1016/S1470-2045(18)30083-4.
Geyer CE. Lancet Oncol. 2018;doi:10.1016/S1470-2045(18)30084-6.
Adding metronomic oral cyclophosphamide, or “soft” chemotherapy, to trastuzumab plus pertuzumab increased median PFS among elderly…
In the Journals Plus

Neoadjuvant dabrafenib, trametinib may improve BRAF-mutant melanoma outcomes

Amaria RN, et al. Lancet Oncol. 2018;doi:10.1016/S1470-2045(18)30015-9.
Ascierto PA and Eggermont AMM. Lancet Oncol. 2018;doi:10.1016/S1470-2045(18)30016-0.
Pre- and postsurgical treatment with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib improved EFS for patients with surgically…
In the Journals Plus

Liquid biopsy predictive of survival for metastatic triple-negative breast cancer

Stover DG, et al. J Clin Oncol. 2018;doi:10.1200/JCO.2017.76.0033.
Bujak AZ, Dawson S. J Clin Oncol. 2018;doi:10.1200/JCO.2017.76.5461.
Liquid biopsy feasibly predicted outcomes among patients with metastatic triple-negative breast cancer, study data showed. “Traditionally, we…
In the Journals Plus

Married patients more likely to find melanoma earlier

Sharon CE, et al. JAMA Dermatol. 2018;doi:10.1001/jamadermatol.2018.0233.
Married patients with melanoma appeared more likely to present with early-stage disease than divorced, widowed or never-married patients, according…
In the Journals Plus

Adjuvant chemotherapy improves OS in rectal cancer

Chang GJ. JAMA Oncol. 2018;doi:10.1001/jamaoncol.2018.0227.
Dossa F, et al. JAMA Oncol. 2018;doi:10.1001/jamaoncol.2017.5597.
Polanco PM, et al. JAMA Oncol. 2018;doi:10.1001/jamaoncol.2018.0231.
Adjuvant chemotherapy appeared associated with improved OS among patients with rectal cancer who achieved pathological complete response after…
In the Journals Plus

Estrogen after oophorectomy does not increase breast cancer risk

Kotsopoulos J, et al. JAMA Oncol. 2018;doi:10.1001/jamaoncol.2018.0211.
The use of estrogen following preventive oophorectomy did not appear to increase the risk for breast cancer among women carrying a BRCA1 mutation…
In the Journals Plus

Selinexor plus dexamethasone active in refractory multiple myeloma

Vogl DT, et al. J Clin Oncol. 2018;doi:10.1200/JCO.2017.75.5207.
Selinexor and dexamethasone showed antimyeloma activity among patients with quad- or penta-refractory disease, according to data published in…
In the Journals Plus

Axitinib plus pembrolizumab promising for late-stage kidney cancer

Atkins MB, et al. Lancet Oncol. 2018;doi:10.1016/S1470-2045(18)30081-0.
Procopio G, et al. Lancet Oncol. 2018;doi:10.1016/S1470-2045(18)30092-5.
Combination therapy with axitinib plus pembrolizumab appeared promising and tolerable among patients with advanced renal cell carcinoma, according to…
Healio Jobs
Personalize your search